Amrix (Cyclobenzaprine Hydrochloride)
Brand Names: Amrix
Methodology & AI Transparency ⓘ
Amrix (Cyclobenzaprine Hydrochloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Cyclobenzaprine Hydrochloride (cross-referenced at /meds/cyclobenzaprine-hydrochloride) and registered by Cephalon, LLC, Amrix operates as a prescription brand-name muscle relaxant therapy (RxNorm 828353; NDC 63459-700, 63459-701).
- 2 Real-world patient consensus: Commercial Amrix monograph (30 mg/1 Capsule, Extended Release) cross-indexed with generic Cyclobenzaprine Hydrochloride for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $24.77 mail/discount cash up to $65.64 uninsured retail (federal NADAC $66.2326).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Amrix (Cyclobenzaprine Hydrochloride): nausea (12.9%), dizziness (7.2%), fatigue (7%).
Ask our AI Specialists anything about Amrix (Cyclobenzaprine Hydrochloride)
Amrix (Cyclobenzaprine Hydrochloride) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Cyclobenzaprine Hydrochloride (cross-referenced at /meds/cyclobenzaprine-hydrochloride) and registered by Cephalon, LLC, Amrix operates as a prescription brand-name muscle relaxant therapy (RxNorm 828353; NDC 63459-700, 63459-701). Under 2024-04-30 FDA labeling for 30 mg/1 Capsule, Extended Release; 15 mg/1 Capsule, Extended Release, 1 Indications and usage amrix: ® (cyclobenzaprine hydrochloride extended-release capsules) is indicated as an adjunct to.
Bioactive Cyclobenzaprine Hydrochloride within Amrix governs muscle relaxant target modulation with class-characteristic hepatorenal disposition. Commercialized across 30 mg/1 Capsule, Extended Release; 15 mg/1 Capsule, Extended Release (registered by Cephalon, LLC, SPL 2024-04-30), Amrix combines branded dosage-form consistency (NDC 63459-700, 63459-701) with transparent cash-pay comparisons spanning $24.77 to $65.64.
Pharmacokinetic profiling of Amrix (Cyclobenzaprine Hydrochloride) demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 6–17 hour t½ intervals for Amrix (Cyclobenzaprine Hydrochloride) with Approximately 49% to 61% enteral uptake across labeled Amrix (Cyclobenzaprine Hydrochloride) strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar amrix (cyclobenzaprine hydrochloride) conjugates, reaching clinical onset within maximum serum exposure occurs 2–5 hours after amrix (cyclobenzaprine hydrochloride) dosing.
Titration schedules for Amrix (Cyclobenzaprine Hydrochloride) (30 mg/1 Capsule, Extended Release → 15 mg/1 Capsule, Extended Release → 30mg Extended Release Capsule) require excluding previous anaphylactoid or exfoliative reaction attributed to amrix (cyclobenzaprine hydrochloride); clinical scenarios where muscle relaxant exposure from amrix (cyclobenzaprine hydrochloride) poses unacceptable risk; real-world patient logs highlight nausea (12.9% of reports), somnolence (7.9% of reports), constipation (7.4% of reports) alongside a 92.00% Worth-It consensus.
Verify medication reconciliation lists so Amrix (Cyclobenzaprine Hydrochloride) is not inadvertently duplicated with another muscle relaxant.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Amrix (Cyclobenzaprine Hydrochloride) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Amrix (Cyclobenzaprine Hydrochloride)
- Clinical scenarios where muscle relaxant exposure from Amrix (Cyclobenzaprine Hydrochloride) poses unacceptable risk
Logged Side-Effect Incidence (14 Reports)
Amrix (Cyclobenzaprine Hydrochloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Amrix (Cyclobenzaprine Hydrochloride))
Human clinical trial evidence for Amrix (Cyclobenzaprine Hydrochloride) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Amrix (Cyclobenzaprine Hydrochloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $66.2326/unit (~$1986.98/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $24.77 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $65.64 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $28.49 / mo | View logs ↓ |
Amrix (Cyclobenzaprine Hydrochloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Amrix (Cyclobenzaprine Hydrochloride) RxNorm Concept ID | 828353 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $66.2326 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $65.64 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $24.77 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 92.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Amrix (Cyclobenzaprine Hydrochloride) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Amrix (Cyclobenzaprine Hydrochloride) (muscle relaxant) monograph synthesizing RxNorm 828353, openFDA FAERS signals, and $24.77–$65.64 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Amrix (Cyclobenzaprine Hydrochloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.